[go: up one dir, main page]

AU2001228625A1 - Composition of antigen and glycolipid adjuvant sublingual administration - Google Patents

Composition of antigen and glycolipid adjuvant sublingual administration

Info

Publication number
AU2001228625A1
AU2001228625A1 AU2001228625A AU2862501A AU2001228625A1 AU 2001228625 A1 AU2001228625 A1 AU 2001228625A1 AU 2001228625 A AU2001228625 A AU 2001228625A AU 2862501 A AU2862501 A AU 2862501A AU 2001228625 A1 AU2001228625 A1 AU 2001228625A1
Authority
AU
Australia
Prior art keywords
antigen
composition
sublingual administration
glycolipid adjuvant
glycolipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001228625A
Inventor
Christopher Wallace Cluff
Garry Elliott
Alan Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergy Therapeutics UK Ltd
Corixa Corp
Original Assignee
Allergy Therapeutics UK Ltd
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9883730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001228625(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergy Therapeutics UK Ltd, Corixa Corp filed Critical Allergy Therapeutics UK Ltd
Publication of AU2001228625A1 publication Critical patent/AU2001228625A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2001228625A 2000-01-14 2001-01-15 Composition of antigen and glycolipid adjuvant sublingual administration Abandoned AU2001228625A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0000891 2000-01-14
GBGB0000891.2A GB0000891D0 (en) 2000-01-14 2000-01-14 Formulation
PCT/GB2001/000142 WO2001051082A1 (en) 2000-01-14 2001-01-15 Composition of antigen and glycolipid adjuvant sublingual administration

Publications (1)

Publication Number Publication Date
AU2001228625A1 true AU2001228625A1 (en) 2001-07-24

Family

ID=9883730

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001228625A Abandoned AU2001228625A1 (en) 2000-01-14 2001-01-15 Composition of antigen and glycolipid adjuvant sublingual administration

Country Status (15)

Country Link
US (1) US8470331B2 (en)
EP (3) EP2322212A1 (en)
JP (1) JP4648603B2 (en)
AR (1) AR027924A1 (en)
AU (1) AU2001228625A1 (en)
CA (1) CA2397359C (en)
CZ (1) CZ304941B6 (en)
DE (1) DE60139305D1 (en)
DK (1) DK2100616T3 (en)
ES (2) ES2328336T5 (en)
GB (2) GB0000891D0 (en)
HU (1) HU230545B1 (en)
PL (1) PL356963A1 (en)
SK (1) SK288411B6 (en)
WO (1) WO2001051082A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
WO2005115449A1 (en) * 2004-05-28 2005-12-08 Alk-Abelló A/S Method of treating allergy and infection by eliciting an iga antibody response
ITMI20061117A1 (en) * 2006-06-09 2007-12-10 Michele Bonanomi A PHARMACEUTICAL COMPOSITION FOR THE SUBLINGUAL ADMINISTRATION OF VACCINI METHOD FOR ITS PREPARATION AND USES
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2484375T (en) 2006-09-26 2018-07-09 Infectious Disease Res Inst Vaccine composition containing synthetic adjuvant
EP2425242B1 (en) 2009-04-29 2019-06-05 Pravin K. Muniyappa Device and method for the diagnosis of gastrointestinal allergy
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
JP5650780B2 (en) 2012-04-04 2015-01-07 日東電工株式会社 Vaccine composition
SG11201407586WA (en) 2012-05-16 2014-12-30 Immune Design Corp Vaccines for hsv-2
HK1214510A1 (en) 2013-04-18 2016-07-29 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
TW201709926A (en) * 2015-04-23 2017-03-16 賽諾菲公司 Glucopyranosyl lipid A and allergen formulations for sublingual administration
WO2017173398A1 (en) 2016-04-01 2017-10-05 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
KR102151962B1 (en) 2020-03-24 2020-09-04 안병철 Method for producing serum composition for preventing or treating infectious disease in young mammal, serum composition produced by the same method, and uses thereof
WO2021194038A1 (en) * 2020-03-24 2021-09-30 안병철 Method for producing serum composition for preventing or treating mucosa-related infectious disease in young mammals, serum composition produced thereby, and use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128637A (en) 1966-09-13 1968-09-25 Beecham Group Ltd Influenza vaccine
US3541201A (en) 1968-12-18 1970-11-17 Ethan Alan Brown Novel sodium chloride encapsulated injectionable substances
GB1377074A (en) 1971-07-13 1974-12-11 Beecham Group Ltd Process for preparing injectable compositions
GB1492973A (en) 1974-02-16 1977-11-23 Beecham Group Ltd Process for preparing injectable compositions
US4070455A (en) * 1974-02-16 1978-01-24 Beecham Group Limited Process for preparing injectable desensitizing compositions and products thereof in microparticle form
EP0182442B2 (en) 1978-12-22 1996-04-03 Biogen, Inc. Recombinant DNA molecules and their method of production
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
DE3521994A1 (en) * 1985-06-20 1987-01-02 Bayer Ag N- (2-AMINOACYLAMIDO-2-DESOXY-HEXOSYL) -AMIDES, CARBAMATES AND UREAS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5244663A (en) * 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
US4975420A (en) * 1987-09-30 1990-12-04 University Of Saskatchewan Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals
FR2621916B1 (en) * 1987-10-19 1990-03-09 Bioeurope WATER-SOLUBLE L-TYROSINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
CA2131442A1 (en) 1992-03-03 1993-09-04 Seishi Tsuchiya Oral vaccine
UA40597C2 (en) * 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition, method for treatment of mammals, diseased or receptive to the infection, method for treatment of mammals with cancer, method for production of vaccine composition, composition of adjuvants
CN1120310A (en) 1993-03-11 1996-04-10 塞科雷泰克公司 Polymeric mucoadhesives in the delivery of immunogens at mucosal surfaces
CN1087176C (en) * 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 Vaccine preparations containing 3-O deacylated monophosphoryl lipid A
DE69426077T3 (en) 1993-05-25 2004-09-02 Wyeth Holdings Corp. ADJUVANTS FOR VACCINE AGAINST THE RESPIRATORY SYNCITIAL VIRUS
WO1995005850A1 (en) * 1993-08-27 1995-03-02 Enteric Research Laboratories, Inc. Campylobacter jejuni antigens, and methods for their production and use
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5514665A (en) 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5646115A (en) * 1994-10-07 1997-07-08 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
WO1996025664A1 (en) 1995-02-17 1996-08-22 Immunotherapy, Inc. Immunotherapy screening, prognosis, and treatment methods and compositions
KR100201352B1 (en) * 1995-03-16 1999-06-15 성재갑 Single injection vaccine formulation
GB9508785D0 (en) 1995-04-29 1995-06-21 Smithkline Beecham Plc Novel compositions
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US5973128A (en) * 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
DE69835424T2 (en) * 1997-03-10 2007-02-08 Immtech Biologics, LLC, Bucyrus BOVINE BREATHING AND DARM CORONAVIRUS AS VACCINE
WO1998043670A2 (en) * 1997-04-01 1998-10-08 Ribi Immunochem Research, Inc. Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
WO1998058956A2 (en) * 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Methods for inducing an immune response involving prime-boost protocols
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
AU750173B2 (en) * 1997-11-10 2002-07-11 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
AU4563099A (en) * 1998-06-11 1999-12-30 Trustees Of The University Of Pennsylvania, The Methods and compositions for delivering proteins to macrophage cells and cells of macrophage derived lineage
CA2330209A1 (en) 1998-06-12 1999-12-23 Smithkline Beecham Biologicals S.A. Recombinant production of toxoplasma sag1 antigen
AU4376199A (en) * 1998-06-26 2000-01-17 Pasteur Merieux Serums Et Vaccins Mucosal targeting immunisation
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
PT1031347E (en) * 1999-01-27 2002-09-30 Idea Ag TRANSNATIONAL TRANSMISSION / IMMUNIZATION WITH MOST ADAPTABLE VEHICLES
CA2366688A1 (en) 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
IL145786A0 (en) 1999-04-23 2002-07-25 M & E Biotech As Method for down-regulating il5 activity
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2000076476A1 (en) 1999-06-11 2000-12-21 Endorex Corporation Adjuvant-containing polymerized liposomes for oral, mucosal or intranasal vaccination
GB9924529D0 (en) * 1999-10-15 1999-12-15 Smithkline Beecham Biolog Novel compounds
DE60123603T2 (en) * 2000-06-14 2007-08-16 William Leslie Diss Porter LIPID TO CHANGE THE DEFENSE SYSTEM
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition

Also Published As

Publication number Publication date
ES2328336T5 (en) 2016-06-21
GB0101035D0 (en) 2001-02-28
HU230545B1 (en) 2016-11-28
DK2100616T3 (en) 2016-02-08
ES2328336T3 (en) 2009-11-12
EP1255563B1 (en) 2009-07-22
ES2561360T3 (en) 2016-02-25
HUP0203972A3 (en) 2011-02-28
AR027924A1 (en) 2003-04-16
US20030165512A1 (en) 2003-09-04
CZ304941B6 (en) 2015-02-04
HUP0203972A2 (en) 2003-03-28
EP1255563A1 (en) 2002-11-13
SK288411B6 (en) 2016-10-03
JP4648603B2 (en) 2011-03-09
CZ20022417A3 (en) 2003-03-12
US8470331B2 (en) 2013-06-25
EP1255563B2 (en) 2016-03-02
DE60139305D1 (en) 2009-09-03
CA2397359C (en) 2012-06-05
EP2322212A1 (en) 2011-05-18
SK10412002A3 (en) 2003-05-02
PL356963A1 (en) 2004-07-12
GB0000891D0 (en) 2000-03-08
WO2001051082A1 (en) 2001-07-19
JP2003519669A (en) 2003-06-24
EP2100616A2 (en) 2009-09-16
EP2100616A3 (en) 2009-09-23
GB2360210A (en) 2001-09-19
CA2397359A1 (en) 2001-07-19
EP2100616B1 (en) 2015-11-25
GB2360210B (en) 2004-12-15

Similar Documents

Publication Publication Date Title
AU2001228625A1 (en) Composition of antigen and glycolipid adjuvant sublingual administration
AU2001255196A1 (en) Compositions and methods for enhancing immunogenicity of antigens
HUP0105473A3 (en) Immunological adjuvant compound and composition containing thereof
EP1291377B8 (en) Silicone compound and cosmetic preparation
AU2000269903A1 (en) Mechanical connection of panels
AU2002225855A1 (en) Preparation of nanocrystallites
AU2001270057A1 (en) Acoustical and thermal insulator
AU3731600A (en) Composition and structures made therefrom
AU2001234437A1 (en) Deicing compositions and methods of use
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2001290239A1 (en) Medicinal composition
AU2001284763A1 (en) Preparation of risperidone
AU6902901A (en) Synchronisation of databases
AU2002216847A1 (en) Epitopes of pai-1
AU2001265280A1 (en) Preparation of 2-hydroxy-5-oxoproline and analogs thereof
AU2001279729A1 (en) Use of cross-linker and compositions made therefrom
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2001286775A1 (en) Adjuvant
AU2001245950A1 (en) Preparation of deoxynucleosides
AU2002212327A1 (en) Pharmaceutical preparation comprised of milk-thistle and terpenes
AU2001267541A1 (en) Vaccine composition
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU2001263511A1 (en) Alkyl glycidyl carbonate compositions and their preparation
AU2001267613A1 (en) Adjuvant composition comprising FHA protein or fragment of FHA protein in free form
AUPQ760400A0 (en) Herbical formulations and methods of use thereof